The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.

By W. Marston, J. Hanft, P. Norwood, R. Pollak. Diabetes Care, 2003

699 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing (2012, background): “Fibroblast delivery of PDGF-BB through an absorbable mesh is a clinically efficacious drug therapy approved by the FDA [297, 298].”
Chronic Wound Healing: A Review of Current Management and Treatments (2017, background): “Numerous studies have borne out its efficacy [46, 47], especially for burn wounds and venous/pressure ulcers, but a few downsides are a theoretical risk of rejection (although unreported thus far) and hypersensitivity (as bovine serum may be contained in trace amounts in the preparation).”
The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. (2016, methodology): “The pivotal study of Dermagraft in DFUs was a singleblinded, randomized, controlled investigation at 35 centers enrolling 314 patients comparing standard DFU care with standard care plus the weekly application of Dermagraft for up to 8 weeks.(144) Clinical studies evaluating Dermagraft and Apligraf ”
Progress and opportunities for tissue-engineered skin (2007, background): “Donor cells need to be from screened donors to avoid viral diseases, and the products that use them (such as Dermagraf”